Merck & Co., Inc. (NYSE:MRK) Releases FY 2026 Earnings Guidance

Merck & Co., Inc. (NYSE:MRK) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 5.040-5.160 for the period, compared to the consensus earnings per share estimate of 5.070. The company issued revenue guidance of $65.8 billion-$67.0 billion, compared to the consensus revenue estimate of $66.5 billion.

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK traded up $2.84 on Friday, hitting $112.02. 8,045,877 shares of the company were exchanged, compared to its average volume of 11,341,904. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The stock’s 50 day moving average price is $117.69 and its 200 day moving average price is $107.39. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The firm has a market capitalization of $276.68 billion, a P/E ratio of 15.39, a price-to-earnings-growth ratio of 2.25 and a beta of 0.26.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The firm had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the company earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Sell-side analysts predict that Merck & Co., Inc. will post 4.89 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on MRK shares. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. Cantor Fitzgerald increased their price target on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Zacks Research upgraded shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. JPMorgan Chase & Co. lifted their price objective on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a report on Monday, April 6th. Finally, TD Cowen increased their target price on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a research note on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $128.18.

Insider Activity

In related news, CMO Chirfi Guindo sold 20,000 shares of Merck & Co., Inc. stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $121.88, for a total value of $2,437,600.00. Following the sale, the chief marketing officer owned 80,615 shares of the company’s stock, valued at approximately $9,825,356.20. This trade represents a 19.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jennifer Zachary sold 121,573 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the sale, the executive vice president directly owned 68,916 shares of the company’s stock, valued at approximately $8,211,341.40. The trade was a 63.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 320,176 shares of company stock worth $38,281,735. Insiders own 0.17% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q1 results beat consensus — revenue of $16.29B and EPS better than expected, driven by Keytruda and other growth products; company raised its adjusted EPS outlook for FY2026. Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
• Positive Sentiment: Product momentum: Winrevair and injectable Keytruda posted strong sales (Winrevair reported ~$525M), helping lift revenue and investor sentiment. Merck Sales Beat As Winrevair Hits $525 Million
• Positive Sentiment: Regulatory/pipeline wins: FDA approval for a new two‑drug HIV regimen (IDVYNSO) and European Commission approval for ENFLONSIA (RSV prevention in infants) broaden Merck’s growth avenues beyond oncology. Merck Expands Beyond Oncology With New HIV RSV Allergy And Rare Disease Bets
• Neutral Sentiment: Guidance and filings: Merck provided FY2026 EPS guidance of $5.040–$5.160 (roughly in line with consensus) and updated revenue targets; the company flagged a tighter sales range even as EPS guidance was maintained. Merck Announces First‑Quarter 2026 Financial Results
• Neutral Sentiment: Pipeline progress: Merck dosed the first patient in Phase 3 studies of enpatoran for lupus skin manifestations — constructive long‑term news but not an immediate revenue driver. Merck Announces First Dose in Phase 3 Study with Enpatoran
• Neutral Sentiment: Analyst moves: Wells Fargo trimmed its price target from $150 to $145 but kept an overweight rating — a modestly less bullish valuation that still implies substantial upside. Benzinga
• Negative Sentiment: GAAP loss and charges: Merck reported a GAAP loss driven by an acquisition‑related Cidara charge, which clouds headline earnings even though adjusted results beat. Merck posts quarterly loss due to Cidara charge, sales rise 5%
• Negative Sentiment: Near‑term risks: Some coverage notes concerns about future pressure on legacy products (HPV vaccine, diabetes drug) and a narrowed sales range, which could cap upside if growth softens. Merck Stock Falls After Earnings. It’s Working on Ways to Blunt Future Lost Keytruda Sales.

Institutional Investors Weigh In On Merck & Co., Inc.

Several large investors have recently bought and sold shares of MRK. Wellington Management Group LLP boosted its stake in shares of Merck & Co., Inc. by 14.8% in the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after acquiring an additional 11,156,354 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Merck & Co., Inc. by 37.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock valued at $1,973,983,000 after purchasing an additional 5,152,069 shares in the last quarter. Marshall Wace LLP boosted its stake in Merck & Co., Inc. by 985.4% during the 4th quarter. Marshall Wace LLP now owns 3,969,469 shares of the company’s stock worth $417,826,000 after purchasing an additional 3,603,769 shares during the last quarter. Federated Hermes Inc. raised its position in shares of Merck & Co., Inc. by 590.9% in the fourth quarter. Federated Hermes Inc. now owns 2,492,038 shares of the company’s stock valued at $262,312,000 after buying an additional 2,131,343 shares during the last quarter. Finally, AQR Capital Management LLC raised its position in shares of Merck & Co., Inc. by 21.3% in the third quarter. AQR Capital Management LLC now owns 10,658,099 shares of the company’s stock valued at $851,369,000 after buying an additional 1,870,827 shares during the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.